AI 研究报告
Eli Lilly and Company（LLY）股票研究 — September 27, 2026
由 Joe (Valarn) 使用 Valarn 创建自本研究生成以来，已有 1 项重要变化：
- •自报告以来披露的国会议员交易：1 笔。
AI 模型共享大量训练数据、并不相互独立，因此它们之间的一致并不代表正确的概率。
此研究生成于 September 27, 2026。此后市场和公司信息可能已发生变化。
Growth strong, price premium, thin cushion
结论
Growth is strong across regions and products, with solid margins. The stock trades at a premium and faces supply and flow headwinds.
LLY’s GLP‑1 engine continues to deliver outsized growth (TTM +65.8%; latest quarter +78.9% YoY) with breadth across geographies and segments, while margins remain elite (83.4% gross; 45.6% operating) and execution consistent (4/4 EPS beats). Valuation is growth‑backed with a forward P/E of 32.4x, a PEG of 0.42, and a current multiple below the 5‑year median band, though peer premiums and a 0.81% FCF yield mean limited cushion if growth slows. Consensus bakes in strong FY2026 EPS (36.58) and +35.8% revenue growth, and options imply a meaningful event window into the 10/29 print. Key watchpoints are any signs of GLP‑1 growth deceleration from the +99.3% Cardiometabolic baseline, operating‑margin slippage from 45.6%, or capacity‑driven allocation/guidance cuts.
支持观点的因素
- Top-line momentum is broad, with TTM revenue up 65.8%.
- Margins are durable, with operating margin at 45.6%.
- Financial strength shows through, with net debt/EBITDA at 1.06x.
不利因素
- Valuation looks stretched with forward P/E at 32.4x and a free-cash-flow yield of 0.8%.
- Revenue is heavily concentrated in Cardiometabolic Health (80.6% of sales), making it vulnerable to GLP-1 shocks.
- Manufacturing and flow risks could constrain growth or lead to guidance cuts.
关键催化剂
- Q3 2026 EarningsOct 29, 2026
主要风险
- GLP-1 concentrationCardiometabolic Health accounts for 80.6% of product revenue, heightening sensitivity to GLP-1 competition or pricing shocks.
- Manufacturing capacityCapacity increases may not keep up with demand, risking allocations or guidance cuts.
- Valuation and flowsPremium vs peers and a very low free-cash-flow yield leave little cushion if growth slows; forward metrics and cash flow expectations add risk.
- Macro/rate riskA sustained rise in rates could squeeze multiples and funding for growth.
AI 辩论
21 位 AI 专家研究了 LLY；随后一位看涨研究员与一位看跌研究员进行了 3 轮辩论。
看涨情景LLY’s hypergrowth and elite margins, paired with a not-stretched forward multiple, set up attractive 12‑month risk/reward with multiple ways to win on execution and catalysts.
看跌情景LLY's premium valuation and extreme reliance on a single, decelerating-risk GLP-1 franchise leave little margin for error against a backdrop of insider selling and sector outflows.
AI 研究团队
- Earnings
- Sector & Peer
- 质量与护城河
- Valuation
- Red Flags
- 期权流向
- 做空兴趣
- Congressional Trading
- 内部人交易动向
- 另外 +12 项
接下来想让 Valarn 研究什么？
像对冲基金一样做研究——先弄懂为什么，再决定买。免费亲自开展研究。
这是研究的公开摘要
完整报告包括完整的 AI 辩论、每位专家的研究、每项论断背后的证据、期权与内部人士分析、回测以及高级风险审查。
认为这个论点有误？
亲自对 LLY 进行研究。若您发布，读者可将两份报告并排对比——看它们在哪里一致、证据在哪里分歧。
质疑这份研究Valarn 1.0.0
仅供教育用途的AI研究。不构成财务、投资、法律或税务建议。不构成买入、卖出或持有任何证券的推荐。内容由AI生成，可能不准确或已过时。请咨询持牌顾问。